Current Report Filing (8-k)
August 13 2021 - 8:10AM
Edgar (US Regulatory)
0001729427
false
0001729427
2021-08-13
2021-08-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
August 13, 2021
___________________________
CNS Pharmaceuticals, Inc.
(Exact name of registrant as specified in its
charter)
___________________________
Nevada
|
001-39126
|
82-2318545
|
(State or other jurisdiction of
incorporation or organization)
|
(Commission File Number)
|
(I.R.S. Employer Identification No.)
|
2100 West Loop South, Suite 900
Houston,
Texas 77027
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code: (800) 946-9185
Not Applicable
(Former Name or Former Address, if Changed
Since Last Report)
___________________________
Check the appropriate
box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
☐ Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by
check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Securities registered pursuant to Section
12(b) of the Act:
Title of each class
|
Trading Symbols(s)
|
Name of each exchange on which registered
|
Common stock, par value $0.001 per share
|
CNSP
|
The NASDAQ Stock Market LLC
|
Item 2.02
|
Results of Operations and Financial Condition.
|
On August 13, 2021, CNS Pharmaceuticals,
Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2021 and
recent operational highlights. A copy of the press release is attached to this report as Exhibit 99.1 and is incorporated by reference
herein.
Item 9.01.
|
Financial Statements and Exhibits
|
(d) Exhibits
Exhibit No.
|
Exhibit Description
|
Signature
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
CNS Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/ Chris Downs
|
|
|
|
Chris Downs
|
|
|
|
Chief Financial Officer
|
|
Dated: August 13, 2021
CNS Pharmaceuticals (NASDAQ:CNSP)
Historical Stock Chart
From Aug 2024 to Sep 2024
CNS Pharmaceuticals (NASDAQ:CNSP)
Historical Stock Chart
From Sep 2023 to Sep 2024